BRIEF published on 04/17/2024 at 16:21, 7 months 3 days ago Fitch Ratings Confirms “BBB+” Rating with Stable Outlook for Amprion Energy Transition Financial Stability Fitch Ratings Amprion GmbH BBB+ Rating
PRESS RELEASE published on 04/17/2024 at 16:16, 7 months 3 days ago Fitch Ratings affirms “BBB+” rating with stable outlook for Amprion Fitch Ratings reaffirms Amprion GmbH's 'BBB+' rating with stable outlook, highlighting the company's solid financial policy and investment-grade rating amidst grid expansion plans Stable Outlook Fitch Ratings Rating Amprion GmbH Grid Expansion
BRIEF published on 04/11/2024 at 10:05, 7 months 10 days ago Amprion Sets Record Investment for Grid Expansion Acceleration Sustainability Energy Transition Investment Increase Grid Expansion Amprion
PRESS RELEASE published on 04/11/2024 at 10:00, 7 months 10 days ago Amprion accelerates grid expansion and invests more than ever before Amprion accelerates grid expansion and invests record €3 billion in 2023. Plans to invest €27.5 billion by 2028. Revenue increased by 37.5% to €4.8 billion in 2023 Revenue 2023 Investment Grid Expansion Amprion
BRIEF published on 04/05/2024 at 15:36, 7 months 15 days ago Moody's Affirms 'Baa1' Rating with Stable Outlook for Amprion GmbH Energy Transition Financial Stability Amprion GmbH Moody's Ratings Grid Expansion
PRESS RELEASE published on 04/05/2024 at 15:31, 7 months 15 days ago Moody‘s affirms 'Baa1' rating with stable outlook for Amprion Moody's affirms 'Baa1' rating with stable outlook for Amprion, a German transmission system operator facilitating energy transition. CFO Peter Rüth emphasizes solid financial policy Energy Transition Moody's Financial Policy Amprion Baa1 Rating
BRIEF published on 03/27/2024 at 12:59, 7 months 25 days ago Amprion GmbH Announces 2023 Annual Results Conference Call Conference Call Financial Year 2023 Annual Results Amprion GmbH Transmission System Operator
PRESS RELEASE published on 03/27/2024 at 12:54, 7 months 25 days ago Amprion GmbH: Invitation to the 2023 annual results conference call for investors and analysts Amprion GmbH invites investors and analysts to the 2023 annual results conference call on 11th April 2024. CFO Peter Rüth will present financial insights. Register to participate Financial Results Conference Call Investors Analysts Amprion GmbH
PRESS RELEASE published on 09/18/2023 at 11:45, 1 year 2 months ago Amprion GmbH: Amprion again achieves excellent ESG rating by Sustainalytics
PRESS RELEASE published on 08/30/2023 at 16:50, 1 year 2 months ago Amprion GmbH: Amprion again successful with green bond in volume of €1.2 billion
Published on 11/21/2024 at 14:15, 8 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 23 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 23 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 23 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 7 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 8 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 48 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 25 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 3 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 38 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 38 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
